# Respiratory Care Devices Market

> Respiratory Care Devices Market Research Report By Device Type (Therapeutic Devices, Monitoring Devices, Diagnostic Devices, Consumables), By Application (Chronic Obstructive Pulmonary Disease, Asthma, Sleep Apnea, Respiratory Distress Syndrome), By End Use (Hospitals, Homecare, Ambulatory Care Centers, Emergency Medical Services), By Patient Type (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Industry Forecast to 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 7.8%
- **2025:** USD 24.8 Billion
- **2035:** USD 52.3 Billion
- **Key Players:** Medtronic, ResMed, Philips Respironics, Drägerwerk, GE Healthcare, Fisher & Paykel Healthcare, Becton Dickinson, Vyaire Medical

**Report ID:** MRFR/MED/5055-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/respiratory-care-devices-market-6517

---

## Market Summary

## Respiratory Care Devices Market Summary

The Respiratory Care Devices Market stood at an estimated USD 24.8 billion in 2025 and is projected to grow from USD 26.6 billion in 2026 to USD 52.3 billion by 2035, advancing at a CAGR of 7.8% across the forecast window. Growth is anchored to two concrete catalysts: expanded national screening programs for chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea, and reimbursement reforms in several OECD economies that now cover home-based ventilation and oxygen therapy. Hospitals remain the largest purchasing channel, but home care is closing the gap quickly.

It’s a gradual move from hospital-only bedside technology to portable, connected devices that patients can use outside of clinical settings. Manufacturers have invested much in smaller compressors, oxygen concentrators that are more efficient with batteries, and CPAP/BiPAP devices that share data—data on adherence, shared with care teams. Several national digital health programs are setting aside dedicated financing for remote respiratory monitoring infrastructure, highlighting the move from device-only sales to connected care ecosystems.

Regionally, North America leads with ~38% of the global sales due to the high prevalence of COPD/asthma and good reimbursement. Asia-Pacific is the fastest developing region due to increasing air pollution-related respiratory disorders and the building of hospital infrastructure. Europe is the second-largest market, spurred by its aging demography and the robustness of its public health screening programs. In the next decade, Asia-Pacific is likely to gradually gain unit volume market share, while North America will remain the leader in revenue.

## Key Report Takeaways

### • By Technology

- CPAP and BiPAP systems represent the largest product category at 22% share of the Respiratory Care Devices Market
- Oxygen concentrators are forecast to be among the fastest-expanding categories through 2035
- Pulmonary function testing equipment is gaining share as early-diagnosis screening programs scale.

### • By Sector

- Hospitals & clinics account for an estimated 46% of the Respiratory Care Devices Market demand.
- Home care settings are growing at a CAGR above the category average as patients shift to at-home therapy.
- Ambulatory surgical centers contribute a smaller but steadily rising share of procurement.

### • By Geography

- North America commands roughly 38% of the global Respiratory Care Devices Market.
- Asia-Pacific is forecast to post the fastest regional CAGR through 2035
- Europe contributes the second-largest regional value base

## Market Size and Forecast (2021–2035)

The figures below are based on publisher analysis of company filings, procurement data and national health expenditure databases and have been cross-checked against macro respiratory-disease prevalence patterns.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising COPD/asthma prevalence | 22% | Global | Long-term | [6] |
| Aging population growth | 18% | NA, Europe, Japan | Long-term | [7] |
| Homecare/telehealth adoption | 16% | Global | Medium-term | [8] |
| Government screening programs | 14% | NA, EU, India | Medium-term | [9] |
| Connected/portable device innovation | 13% | Global | Short-term | [10] |
| Air pollution-linked disease burden | 10% | Asia-Pacific | Long-term | [11] |
| Public health infrastructure investment | 7% | Emerging markets | Short-term | [12] |

### Disease Burden and Screening Expansion

Several national health systems have widened COPD and sleep-apnea screening eligibility over the past two years, directly increasing diagnostic device procurement. The Global Initiative for Chronic Obstructive Lung Disease estimates COPD affects several hundred million people worldwide, and broader screening criteria in countries such as the UK and Germany have pushed forward diagnostic spirometer demand.

### Homecare Shift and Reimbursement Reform

Reimbursement reform has been a decisive accelerant. U.S. Medicare policy updates expanding home oxygen and ventilator coverage, alongside comparable moves in parts of the EU, have shifted a meaningful share of purchasing from hospital capital budgets to home-health and durable medical equipment channels.

### Connected Device Innovation

Manufacturers have prioritized Bluetooth- and cellular-enabled CPAP, oxygen concentrator, and ventilator platforms that stream adherence and physiological data to clinicians, supporting value-based care contracts that reward documented compliance over device sales alone.

## Restraints

## Restraints Impact Analysis

Restraint impacts are directional estimates of downward pressure on growth and are not strictly additive.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High device cost & reimbursement gaps | -15% | Emerging markets | Medium-term | [13] |
| Lengthy regulatory approval cycles | -11% | Global | Long-term | [14] |
| Device recalls & quality concerns. | -9% | NA, EU | Short-term | [15] |
| Homecare staffing shortages | -8% | NA, Europe | Medium-term | [16] |
| Component supply chain disruption | -6% | Global | Short-term | [17] |

### Reimbursement and Affordability Gaps

In lower- and middle-income markets, out-of-pocket costs for oxygen concentrators and CPAP systems still exceed what most households can absorb without insurance support, slowing adoption even where prevalence data justify stronger demand.

### Regulatory and Quality Friction

Tightened post-market surveillance requirements following past ventilator and CPAP recalls have lengthened approval timelines for new entrants, particularly in the EU under MDR transition requirements, creating a temporary drag on new product launches.

## Opportunities

## Respiratory Care Devices Market Opportunities

### Connected Remote Monitoring

Cloud-linked respiratory devices that feed adherence and vital-sign data into clinician dashboards open recurring-revenue service contracts layered on top of hardware sales.

### Emerging Market Expansion

India, Southeast Asia, and parts of Sub-Saharan Africa remain significantly underserved relative to disease burden, presenting long-run volume opportunity as public procurement programs scale local distribution.

### Data and Subscription-Based Models

Respiratory-as-a-service contracts, bundling devices, consumables, and remote monitoring under a subscription fee, are emerging as an alternative to one-time capital purchases, particularly across hospital networks managing fleet-wide ventilator costs.

### Home Sleep Apnea Testing Growth

Simplified at-home diagnostic kits are reducing dependence on overnight sleep-lab capacity, expanding the addressable population for downstream CPAP/BiPAP therapy.

### AI-Enabled Diagnostics

Algorithmic analysis of spirometry and overnight oximetry data is improving early detection accuracy, creating a software attach opportunity alongside traditional hardware sales.

## Future Outlook

## Respiratory Care Devices Market Future Outlook

### AI-Enabled Predictive Monitoring

Predictive algorithms layered onto continuous oximetry and spirometry data are expected to shift care from reactive treatment toward early intervention, reducing acute exacerbation hospitalizations.

### Platform and Subscription Economics

Device makers are increasingly bundling hardware, consumables, and data services into recurring contracts, mirroring broader medtech-as-a-service trends across the industry.

### Sustainability and Device Lifecycle Management

Manufacturers face growing pressure to address device recyclability and battery lifecycle impact, particularly under EU sustainability reporting expectations affecting medical device producers.

### Decentralization of Respiratory Care

The center of care continues moving from hospital wards to homes, supported by smaller, quieter, and more energy-efficient device designs suited to daily home use.

## Segment Insights

## Respiratory Care Devices Market Segmentation

### By Product Type

| Segment | Share (%) | Primary Demand Driver |
| --- | --- | --- |
| CPAP & BiPAP Systems | 22% | Rising sleep apnea diagnosis rates |
| Ventilation Support Devices | 18% | ICU and home care ventilator demand |
| Oxygen Concentrators | 17% | Portable home oxygen therapy growth |
| Nebulizers | 15% | Pediatric and asthma management demand |
| Pulmonary Function Testing | 14% | Expanded COPD screening programs |
| Other (Humidifiers, Accessories) | 14% | Consumables replacement cycles |

CPAP and BiPAP systems lead the Respiratory Care Devices Market on the back of widening sleep-apnea diagnosis. At the same time, ventilation support devices retain a strong base from both critical-care and growing home-ventilation use cases.

### By End User

| Segment | Share (%) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Clinics | 46% | Critical care and surgical procedure volume |
| Homecare Settings | 36% | Reimbursement-supported home therapy |
| Ambulatory Surgical Centers | 10% | Outpatient procedure growth |
| Diagnostic Centers | 8% | Standalone pulmonary testing demand |

Home care is the fastest-expanding end-user segment of the Respiratory Care Devices Market as payers increasingly favor lower-cost home-based management over extended hospital stays.

### By Application

| Segment | Share (%) | Primary Demand Driver |
| --- | --- | --- |
| COPD | 32% | An aging population and pollution exposure |
| Obstructive Sleep Apnea | 29% | Rising diagnosis and awareness |
| Asthma | 21% | Pediatric and adult prevalence growth |
| Other Respiratory Disorders | 18% | Broader pulmonary disease screening |

COPD leads respiratory application demand with a 32% share, driven by an aging population and rising pollution exposure. Obstructive sleep apnea follows closely at 29%, propelled by growing diagnosis rates and heightened awareness of the condition. Asthma accounts for 21% of the market amid increasing prevalence across both pediatric and adult populations, while other respiratory disorders (18%) benefit from the expanding scope of broader pulmonary disease screening.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Share (%) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38% | Reimbursement-driven home care expansion |
| Europe | 27% | MDR compliance, aging population demand |
| Asia-Pacific | 22% | Pollution-linked disease burden, hospital build-out |
| South America | 7% | Public procurement program expansion |
| Middle East & Africa | 6% | Hospital infrastructure investment |
| Total | 100% | — |

### North America

| Country | Share of Region (%) | Key Driver |
| --- | --- | --- |
| United States | 84% | Medicare home-oxygen coverage expansion |
| Canada | 11% | Provincial home care funding |
| Mexico | 5% | Private hospital capacity growth |

Demand in the United States continues to be shaped by CMS coverage policy for home respiratory equipment, while Canadian provinces have steadily widened durable medical equipment funding for COPD patients.

### Europe

| Country | Share of Region (%) | Key Driver |
| --- | --- | --- |
| Germany | 22% | Statutory health insurance reimbursement |
| United Kingdom | 18% | NHS COPD screening expansion |
| France | 14% | Homecare service network growth |
| Rest of Europe | 46% | MDR-driven product modernization |

Germany's statutory insurance framework continues to support relatively high per-capita device spending, while the UK's NHS long-term plan has expanded community-based respiratory screening.

### Asia-Pacific

| Country | Share of Region (%) | Key Driver |
| --- | --- | --- |
| China | 30% | Hospital infrastructure expansion |
| Japan | 20% | An aging population demands |
| India | 18% | Public procurement scale-up |
| South Korea | 12% | Homecare reimbursement reform |
| Australia | 8% | Private insurance coverage growth |
| Rest of Asia-Pacific | 12% | Pollution-linked disease burden |

China's continued hospital capacity build-out and India's national procurement initiatives are jointly pulling regional volume growth above the global average.

### South America

| Country | Share of Region (%) | Key Driver |
| --- | --- | --- |
| Brazil | 58% | Public health system procurement |
| Rest of South America | 42% | Private hospital network growth |

Brazil's public health system remains the dominant procurement channel, with growing private-sector participation in major urban centers.

### Middle East & Africa

| Country | Share of Region (%) | Key Driver |
| --- | --- | --- |
| UAE | 24% | Private hospital investment |
| Saudi Arabia | 22% | Vision 2030 healthcare infrastructure spend |
| Rest of Middle East & Africa | 54% | NGO and donor-funded program expansion |

Saudi Arabia's healthcare infrastructure investment under its national transformation program continues to support new hospital respiratory-unit procurement.

## Competitive Benchmarking

## Competitive Benchmarking

The Respiratory Care Devices Market is moderately concentrated, with the top five companies accounting for an estimated 45-55% of the global revenue market, with a long tail of regional and specialist manufacturers accounting for the rest.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Medtronic | ~9–12% | Ventilators, monitoring systems | Hospital-focused portfolio breadth |
| ResMed | ~8–11% | CPAP, BiPAP, connected health platforms | Homecare and digital-health leadership |
| Philips Respironics | ~7–10% | Sleep & respiratory devices | Post-recall quality rebuild focus |
| Drägerwerk | ~6–9% | ICU ventilators, anesthesia systems | Critical-care depth |
| GE Healthcare | ~5–8% | Hospital respiratory monitoring | Integrated hospital systems |
| Fisher & Paykel Healthcare | ~5–7% | Humidification, nasal high-flow therapy | Niche therapy innovation |
| Becton Dickinson | ~4–6% | Diagnostic and monitoring consumables | Broad consumables distribution |
| Vyaire Medical | ~3–5% | Ventilators, diagnostics | Mid-market hospital focus |
| Hamilton Medical | ~3–5% | Critical-care ventilators | Specialty ICU ventilation |
| Invacare | ~2–4% | Homecare oxygen & mobility devices | Homecare channel specialist |

## Recent News & Developments

## Recent News & Developments

- ResMed (2024): Expanded its connected-CPAP data platform with broader clinician dashboard integration, reinforcing its subscription-style adherence monitoring model [[18]](https://fphcare.com)
- Philips (2023): Continued post-recall remediation and relaunch of sleep and respiratory devices under updated quality protocols [[19]](https://health.ec.europa.eu)
- Medtronic (2024): Announced portfolio expansion in portable ventilation aimed at home care and transport use cases [[20]](https://cms.gov)
- Drägerwerk (2023): Introduced updated ICU ventilator software focused on lung-protective ventilation algorithms
- U.S. CMS (2024): Updated home respiratory equipment coverage policy, broadening eligibility for oxygen therapy reimbursement [[22]](https://vision2030.gov.sa)
- Fisher & Paykel Healthcare (2025): Expanded nasal high-flow therapy manufacturing capacity to meet rising hospital demand
- EU MDR (2024): Continued phased enforcement affecting respiratory device recertification timelines across European manufacturers
- Vyaire Medical (2023): Entered a distribution partnership to expand ventilator access across Southeast Asian hospital networks

## Report Scope

## Respiratory Care Devices Market Report Scope

| Item | Detail |
| --- | --- |
| Market Scope | Global Respiratory Care Devices Market by product, end user, application, and region |
| Study Period | 2021–2035 |
| CAGR | 7.8% (2026–2035) |
| Market Size Checkpoints | 2025 base year: USD 24.8B; 2035 forecast: USD 52.3B |
| Fastest Growing Segments | Oxygen Concentrators (product); Homecare (end user) |
| Companies Profiled | 10 leading global and regional manufacturers |
| Valuation Currency | USD |

## Frequently Asked Questions

**Q: What should buyers prioritize when comparing respiratory device vendors?**
A: Service and data-integration support matter as much as device specifications. Vendors offering remote monitoring and adherence reporting reduce long-term clinical workload [Ref 18].

**Q: How does MDR compliance affect procurement timelines in Europe?**
A: Recertification under MDR has extended product launch timelines for several manufacturers. Buyers should confirm certification status before committing to multi-year contracts [Ref 19].

**Q: What integration challenges arise with connected respiratory devices?**
A: Hospital IT systems often require custom interfaces to ingest device data. Procurement teams should evaluate interoperability standards before deployment [Ref 18].

**Q: Are subscription-based device models gaining traction?**
A: Yes, bundled hardware-plus-monitoring contracts are emerging, especially in home care. They shift the cost from upfront capital to predictable recurring fees [Ref 21].

**Q: How does reimbursement policy vary by region for home care devices?**
A: Coverage differs significantly; U.S. Medicare and several EU systems fund home oxygen, while many emerging markets still require out-of-pocket payment [Ref 20].

**Q: What competitive risks exist for smaller respiratory device manufacturers?**
A: Smaller players face pricing pressure from consolidated leaders and rising regulatory compliance costs, making partnerships or niche specialization important [Ref 14].

**Q: What emerging use cases are expanding beyond traditional respiratory therapy?**
A: Home sleep apnea testing and AI-assisted spirometry are extending device use into earlier-stage diagnosis, beyond established chronic-care management [Ref 10].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/respiratory-care-devices-market-6517*